SECTOR : Biotech
ENTRY DATE : 2010
EXIT DATE : 2019
BUSINESS : Venture Capital
Next-generation stents used in the treatment of heart attacks
Stentys develops and markets innovative solutions used to treat patients presenting complex coronary conditions. Stentys’ self-apposing stents are designed to adapt to arteries with ambiguous vessel diameters or with areas of vessel diameter fluctuations so as to avoid the mal-apposition issues associated with conventional stents. The Apposition III clinical study showed a very low 1-year mortality rate among 1,000 high-risk patients treated for myocardial infarction, compared with recent studies on conventional stents.
October 2010: Stentys (STNT) successfully raised €22.7 million in an IPO.
Market capitalisation at IPO date: €87 million
PRESS RELEASE(S) :
29/06/2009• Stentys closes $22+ million Series ‘B’ total financing led by Sofinnova Partners and Scottish Equity Partners (SEP) with $4.2 million from new investor Crédit Agricole Private Equity